Thu, Mar 5, 2015, 11:21 AM EST - U.S. Markets close in 4 hrs 39 mins


% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. (SNTA) Message Board

ajetjock 61 posts  |  Last Activity: Feb 23, 2015 8:35 AM Member since: Mar 11, 1998
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • The analyst rates IPCI a Buy with an $8 price target, which implies an upside of 270% from current levels.

    Sentiment: Strong Buy

  • IPCI will likely move past previous high of 6.5.

    They thrive during periods of no - news. Where they can float FEAR and innuendos.

    Nothing factual.

    Same ol' stuff in shorty's world.

    Sentiment: Strong Buy

  • ajetjock ajetjock Jan 30, 2015 2:56 PM Flag

    A bump above the Peckerstein , MEifud Gregory, stench.

    Sentiment: Strong Buy

  • ajetjock ajetjock Jan 30, 2015 2:55 PM Flag

    This is a bump of the FACTS, above the stench of the shorts occupying this board : Gregory, Meifud, Peckerstein .

    Sentiment: Strong Buy

  • When you screw up with your LIES, STOP digging deeper.

    This has NOTHING to do with IPCI.

    You KNEW it. You were TOLD about it, yet you keep on REPEATING the lie.

    Here is a sugestion: Go find a stock you actually like... or look for a job where you do not have to resort to ILLEGAL activity of MANIPULATING stocks.

    Sentiment: Strong Buy

  • Shorts try to manipulate stocks. That is what they do ! They do it by creating FEAR and uncertainty using same ol' "buzz" words.

    In IPCI's case, they now resort to LIES. Flat out LIES. Folks, posting bogus information to MANIPULATE share price is as ILLEGAL as it gets !

    The usual suspect here are telling you that IPCI has NO ANDAs pending...

    They tell you that the FDA has new procedure and IPCI has to resubmit their applications.

    They tell you that IPCI is not "grandfathered"....

    Well, HOW did the shorts come up with this utter load of nonsense ?

    The only explanation could be that they picked up on ONE piece of news and TWISTED it into a complete LIE. The news is (Google it ! 11/17/2014) "FDA Drop A Bombshell on Slow Release Generic Drugs" .

    They (FDA) are talking about Concerta.

    Well folks, this has *ABSOLUTELY NOTHING* to do with IPCI ! Not a THING !

    IPCI is NOT using this process and there is NO NEW application process requirement for IPCI to refile ANY of their ANDAs !

    In short, IPCI ANDAs, ***ALL OF THEM*** are still awaiting approval. There is NOTHING IPCI has to do but wait.

    Folks, IF you believe ANYTHING Peckerstein, Meifud and Gregory are saying, and base your investment decisions on their LIES, you WILL regret it.

    Think about it: Why would these three stooges hang around a stock they obviously do not like every day, 365 days per year...for years ???

    Because their sole purpose in life is to push the price DOWN. They ARE shorts, or are working for shorts.

    But when they flat out LIE with "news" that do not exist or apply to IPCI, they have crossed the line.

    And that is GREAT news for IPCI because it has become obvious the shorts have ran out of ammunition. Their usual B. $ just does not work.

    FWIW I have not sold ONE share of IPCI and at this level, with 10 pending ANDAs, the stock is a gift.

    Have a great Super ball weekend longs, and if you are Chinese: Happy New Year !

    Sentiment: Strong Buy

  • Fr a 2014 interview:

    " In terms of the regulatory queue, do larger pharmaceutical companies like Teva have an advantage over smaller companies like Intellipharmaceutics, or is it more in terms of whichever company is first in line?

    The whole ANDA process that the FDA is triaging and the way that companies communicate with the FDA have changed significantly in the last 12 months. This is because of the Generic User Fee Act and because the FDA is trying to become much more efficient in dealing with the backlog of almost 3,000 ANDAs that have been filed with them.

    As you've pointed out, there are more well financed competitors out there, so what differentiates Intellipharmaceutics in ways that you would consider advantageous?

    The way I like to explain to people how we build the business is using the baseball analogy. Our ANDAs are like a bunch of singles and doubles. So we have a number of them lined up (pipeline on website), and even if a couple of them strike out, we still got a number of singles and doubles. And with that alone, we can win the game, and we'll continue to file more ANDAs as time moves on. So, if you can get 10 products that are generating $5 million a year in revenues, you actually have a nice little portfolio, and that's effectively the base of the company. But, what are the homerun potentials using the baseball analogy? Well, our Rexista oxycodone could have homerun potential because the FDA has said point blank that it wants drug abuse deterrent technology implemented in narcotics [indiscernible]. That's exactly the space that we're moving forward with. So, Rexista has homerun potential because there is a separate regulatory path that's not as simple as the ANDA path, but it's not as long and as cumbersome as the biotech path (the Phase 1-3). Our Rexista oxycodone is going down a quicker regulatory path that has pretty good reward potential. "

    Sentiment: Strong Buy

  • Reply to

    It appears a Div cut is ALREADY baked in the PPS.

    by check__6 Jan 29, 2015 10:51 AM
    ajetjock ajetjock Jan 29, 2015 1:01 PM Flag

    Chart looks like a nice flag is forming as the range is narrowing around 4 .

    Sentiment: Strong Buy

  • Reply to

    ONE Fact for New investors:

    by ajetjock Jan 29, 2015 9:12 AM
    ajetjock ajetjock Jan 29, 2015 11:57 AM Flag

    What games ?

    You can play with yourself all day long.

    I have better things to do than sit around all day and scare investors by trying manipulating stocks.

    BTW, I am NOT a kid. Been investing for DECADES and seen the likes of you multiplying like roaches over the internet.

    Sentiment: Strong Buy

  • " What's your overview on the future of your niche or specialization in the drug delivery industry?

    Well, the specialization of drug delivery has been going in a lot of different directions. You can find drug delivery companies that are very much focused on injectables, and others which are focusing on transdermal applications. Our drug delivery solutions are all oral solid dosage forms (pills and caps). So, our controlled release formulations are really surrounding oral solid dosage forms.

    The typical life cycle management strategy of Big Pharma is that they come out with a drug, such as Pfizer's Lyrica, which brings in around $2.8 billion a year in the US. Lyrica is a 2-to-3-times-a-day drug. Pfizer's patent for Lyrica is going to expire in 2017 or 2018. As a result, Pfizer is in the process of developing, filing and ultimately receiving approval for a once-a-day formulation of Lyrica. Thus, the life cycle management strategy of Big Pharma is to move patients on a more convenient dosage form (once a day) as patents expire, which actually improves compliance. For instance, think about yourself. Think about how many times you've missed a dose of a medication taken two or three times daily. But if you can take it only once a day, you're good for the entire day (and less likely to forget doses). So, people actually prefer once-a-day formulations. "

    Sentiment: Strong Buy

  • " What makes our company interesting at this juncture is that, for the very first time, we have revenues. Trailing 12-month revenue is $7.7 million and we have analyst coverage from four firms.

    So, Intellipharmaceutics is a specialty pharmaceutical company, but under that umbrella name for specialty pharmaceuticals, we are in the drug delivery space. Our drug delivery technologies are really controlled drug delivery release technologies. These controlled release technologies fit into three baskets:

    The first basket is our abuse resistance drug delivery platform, which is called Rexista. We have some Phase 1 data on our Rexista oxycodone, and we'll have some additional data later on this year.
    The second basket is our once-a-day formulations of drugs where once-a-day doesn't exist. We've done that with Pfizer's (NYSE:PFK) Lyrica. The generic name for Lyrica is Pregabalin, so we are working on providing Phase 1 data on that, and we should have additional data later on this year.
    The third basket is our generic portfolio. We can actually create copycat generics of once-a-day formulated drugs. We do this without reverse engineering the innovator's patented XR technologies. We use our own XR technologies to create these once-a-day XR generics. Our marketed product is Focalin XR, which received approval in November 2013. We have seven other drugs filed with the FDA that are generic equivalents and are XR formulations.
    So, we have quite a lot of products, and our patents surrounding our drug delivery solutions are not involved in the typical biotech companies developing novel drugs. Our patents are around our drug delivery solutions, which are our own proprietary methods of delivering drugs. "

    Sentiment: Strong Buy

  • Gregory , Meifud and Peckerstein, possibly same person. Either way ARE very likely PAID bashers trying to manipulate the price down.

    Every board has its bad elements. These 3 IDs have been here for YEARS to tell us all that is bad with IPCI.

    You should ask yourselves: WHY ?

    During the time these 3 stooges have been here 24/7/365 IPCI has moved from LESS than a dollar to 6.5 FAST after their FIRST drug was approved.

    Back then the paid bashers, simply DISAPPEAR !

    They WILL disappear again as we get more FDA approvals.

    Don't allow MANIPULATORS, steal your money !

    Sentiment: Strong Buy

  • Maybe you clowns need to look for another line of work ?

    We GOT your point few years ago: You don't like IPCI.

    Now move on and get a life ! You are not getting younger bashers !

    Go find a girl friend...hobby...anything. Just stop ridiculing yourselves here with same ol' repetitive nonsense.

    Sentiment: Strong Buy

  • Just curious...

    Hugs and kisses XOXOX

    Sentiment: Strong Buy

  • Reply to

    FACT : IPCI Top Institutional holders:

    by ajetjock Jan 27, 2015 12:53 PM
    ajetjock ajetjock Jan 27, 2015 3:36 PM Flag


    Contrary to Pecker-Me-Greg (AKA- Shorty bashers.) constant BS, this institutional holding list IS CURRENT as of : TODAY !

    Sentiment: Strong Buy

  • Top Mutual Fund Holders
    Percentage of Outstanding Shares per Holdings Style

    Sector Specific 6.3%
    International 0.7%
    Specialty 0.0%
    Core Growth 0.0%
    Index 0.0%
    Avg. Turnover Rating

    Shares Held
    Position Value
    Percentage of
    Total Holdings
    since 1/27/15
    % Owned
    of Shares
    Outstanding Investment
    H&Q Healthcare ...

    828.4K $2,508,164 +10% 3.6% Sector Specific
    H&Q Life ...

    575.6K $1,742,961 +7% 2.5% Sector Specific
    FCP OP Medical ...

    164.4K $497,660 +2% 0.7% International

    28.3K $85,737 0% 0.1% Sector Specific
    RIM Global Fund ...

    17.9K $51,357 0% 0.1% Sector Specific
    Fidelity NASDAQ ...

    5.0K $14,335 0% 0.0% Index
    CF Equities HAIG ...

    660.0 $1,897 0% 0.0% Core Growth

    Top Institutional Holders
    Concentration of Current % Held
    Top 10 Institutions: Ownership by top 10 institutions Top 20 Institutions: Ownership by top 20 institutions Top 50 Institutions: Ownership by top 50 institutions All: Ownership by all institutions
    Avg. Turnover Rating

    Shares Held
    Position Value
    Percentage of
    Total Holdings
    since 1/27/15
    % Owned
    of Shares
    Outstanding Turnover
    Odidi Holdings, Inc.

    6.0M $23,093,293 +71% 25.7% Low
    Tekla Capital ...

    1.4M $4,251,125 +17% 6.0% Moderate
    Oppenheim Asset ...

    192.7K $583,397 +2% 0.8% Low
    Medical Strategy ...

    182.2K $523,714 +2% 0.8% Moderate
    Allport (John N)

    110.6K $425,684 +1% 0.5% Low
    Morgan Stanley ...

    96.6K $292,492 +1% 0.4% Low
    NHP Asset ...

    75.0K $227,090 +1% 0.3% Moderate
    Dafna Capital ...

    72.8K $220,389 +1% 0.3% Moderate
    First Midwest ...

    49.4K $149,492 +1% 0.2% Low
    Susquehanna ...

    42.1K $127,576 +1% 0.2% Moderate

    Sentiment: Strong Buy

  • Must have run out of new FEAR creating ideas .

    They are re-posting old garbage such as "institutions are leaving IPCI...bla..bla

    Just dream up garbage and hope it'll stick .

    I agree with another poster : These fools MUST be paid bashers. They simply don't have enough sense to be investors. Not even short ones.

    Sentiment: Strong Buy

  • ajetjock by ajetjock Jan 27, 2015 11:59 AM Flag

    Oil is NOT going to 25. It is about as low as it goes.

    Sentiment: Strong Buy

  • Reply to

    Short Sales are down

    by samsa1 Dec 17, 2014 11:41 AM
    ajetjock ajetjock Jan 27, 2015 9:18 AM Flag

    Because even shorts should know that going short on IPCI is like a Russian Roulette.

    (Although...looking at the dumb shorts here, nothing will surprise me...)

    We all know there are 10 drugs in IPCI's pipeline and several have been at the FDA for quit some time.

    We all remember the day the shorts evaporated into thin air, and IPCI shot to 6.5 in NO TIME :

    "IntelliPharmaCeutics Rips 162% Higher on an FDA Approval

    By Brian Wilson-Lead Contributor
    Wednesday, 20 November 2013 08:57

    Yesterday’s trading was overwhelmingly bullish for the controlled release and targeted drug developer Intellipharmaceutics (NASDAQ: IPCI) after the FDA gave final approval to the company’s dexmethylphenidate hydrochloride extended-release capsules at the 15 and 30 mg doses on Monday night. Tuesday morning (yesterday) the company opened at $3.42 and surged higher throughout the trading day, pausing at the psychological $5/share barrier for the rest of the day.
    In this morning’s premarket trading, it appears that more buyers have been drawn to the stock. At time of writing, the stock is trading another 11% higher, at $5.50/share."

    IPCI continued to 6.5.

    Shorts VAPORIZED !

    Sentiment: Strong Buy

  • Reply to

    Mini lift off today

    by aaa_docs Jan 26, 2015 1:14 PM
    ajetjock ajetjock Jan 26, 2015 2:09 PM Flag

    I don't think that is the case.

    Clearly the float would not have been this small otherwise.

    The only reason IMO the stock is down this far is lack of news coupled with never ending 3-4 shorts spewing
    drivel 24/7/365 on internet boards.

    ...coupled with low float, eventually the shorts starting to dictate the direction. Even though it has NOTHING to do with the merit of the company.

    Longs should never allow SHORTS agenda to dictate how they invest.

    Think about it: Why are these SAME useless pri@ks on here daily with the same BS hanging around a stock they DON'T like ?

    Answer: to SCARE the hell out of LONGS.

    Don't fall for it.

    Sentiment: Strong Buy

2.575+0.145(+5.97%)11:20 AMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.